Practice Alert for the Perioperative Management of Patients with. The process responsible for stent stenosis is delayed with drugs (sirolimus [rapamycin] and paclitaxel); however this benefit is offset by harm due to stent thrombosis (0.2-1.1%). Nov 19, 2008. A major concern after successful coronary artery stent placement is the. The 2007 Science Advisory and the 2007 ACC/AHA. Guidelines.
Clopidogrel after drug-eluting stent implantation Therapeutics. Dual antiplatelet therapy is recommended to decrease the rate of stent thrombosis. Dec 19, 2007. Home Drug Assessments Clopidogrel after drug-eluting stent. Search strategy Databases searched include – Medline 1966-May 2007.
Clopidogrel use and long-term clinical outcomes after drug-eluting. Thrombosis of a drug-eluting stent (DES) is a catastrophic complication. JAMA. 2007 Jan 10;2972159-68. Epub 2006 Dec 5. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. Eisenstein EL1.
CAUTION MAINTAIN ANTI-PLATELET THERAPY IN PATIENTS. Many advances have been made in the percutaneous treatment of coronary artery disease during the past 30 years. Doi 10.2344/0003-3006200754161CMATIP2.0. consisting of aspirin and a thienopyridine drug such as clopidogrel Plavix or ticlopidine Ticlid should. Patients at even hher risk for stent thrombosis such as those with acute coronary.
Plavix Clopidogrel Effient Prasugrel Aspirin After Stent, Allergic. JAMAJAMA Cardiology JAMA Dermatology JAMA Facial Plastic Surgery JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Leon MB, Baim DS, Popma JJ. Stent Anticoagulation Restenosis Study Investators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. 1998;365-1671Pub Med Article Berger PB, Mahaffey KW, Meier SJ. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. 2002;11-846Pub Med Article Spertus JA, Kettelkamp R, Vance C. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. 2006;103-2809Pub Med Article Regar E, Lemos PA, Saia F. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. 2004;71-1275Pub Med Article Ong AT, Hoye A, Aoki J. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. 2005;7-953Pub Med Article Pfisterer M, Brunner-La Rocca HP, Buser PT. J Am Coll Cardioldoi:10.1016/20Thom T, Haase N, Rosamond W. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2006;113:e85-e151Pub Med Article Steinhubl SR, Berger PB, Mann JT III. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. 2002;211-2420Pub Med Article Harrington RA, Califf RM. Apr 23, 2005. After receiving two DES stents in early 2007 in the US I was placed on one 75M Plavix and a 325M Aspirin daily. After moving to Germany I.
Cardiology Experts Share Perspective on Stents Kempen for his letter hhting the challenges of caring for patients with coronary drug-eluting stents (DES). The purpose of the 2007 AHA/ACC/SCAI/ ACS/ADA Science Advisory was to. In these patients, indefinite clopidogrel Plavix® use may be recommended.
Plavix stent 2007:
Rating: 98 / 100
Overall: 87 Rates